5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as CXCR2 antagonists

Details for Australian Patent Application No. 2007323336 (hide)

Owner Novartis AG

Inventors Press, Neil John; Spanka, Carsten; Porter, David

Agent Davies Collison Cave

Pub. Number AU-A-2007323336

PCT Pub. Number WO2008/061741

Priority 06124679.9 23.11.06 EP

Filing date 21 November 2007

Wipo publication date 29 May 2008

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/522 (2006.01)

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

Event Publications

7 May 2009 PCT application entered the National Phase

  PCT publication WO2008/061741 Priority application(s): WO2008/061741

7 June 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007323351-Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

2007323335-Pyrimidines and their use as CXCR2 receptor antagonists